Lack of evidence for <it>KRAS </it>oncogenic mutations in triple-negative breast cancer
<p>Abstract</p> <p>Background</p> <p>Mutational analysis of the <it>KRAS </it>gene has recently been established as a complementary <it>in vitro </it>diagnostic tool for the identification of patients with colorectal cancer who will not benefit f...
Main Authors: | Vicioso Luís, Pérez-Rivas Luís G, de Luque Vanessa, Gallego Elena, Sánchez-Muñoz Alfonso, Ribelles Nuria, Lozano José, Alba Emilio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-04-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/136 |
Similar Items
-
Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
by: Reina E Ito, et al.
Published: (2021-01-01) -
Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
by: Wiesława Niklińska, et al.
Published: (2009-05-01) -
Oncogenic KRAS Expression and Signaling
by: Lampson, Benjamin Logan
Published: (2012) -
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
by: Yasmine White, et al.
Published: (2016-02-01) -
Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01)